PL
PL

We care for the health

of tens of millions of Poles.

The Diagnostyka Group is a leading provider of diagnostic services with the largest network of medical laboratories and sample collection facilities in Poland. The Group began operations in 1998 and has since built a market-leading position in terms of the number of laboratories and sample collection facilities operated, the total number of tests performed, the number of specialists employed and the size of its own courier network. The Group operates in both the B2B and B2C segments, offering professional services including the collection and transport of biological material, the performance of tests and the delivery of results of the highest quality medical analyses in the shortest possible time. Thanks to its unique achievements, Diagnostyka has built one of the most recognisable health care brands in Poland.

The Diagnostyka Group offers more than 4,000 types of tests — from basic screening tests to highly specialised ones. In 2023, the Group performed more than 140 million tests for more than 20 million patients (understood by the Group as the total number of patients provided with tests per day on an annual basis) and gained the trust of more than 11,500 active B2B customers throughout the country.

The full range of diagnostic services offered by the Group encompasses the laboratory testing segment (including general tests such as analytical, microbiological or serological tests, as well as histopathology and genetic tests) and diagnostic imaging. The comprehensiveness of services is a key element in the Group’s development. In addition, the Group is actively developing activities in the area of preventive and personalised medicine, responding to the latest trends in health care.

Multidimensional growth strategy with limited risk

The Group is expanding through a synergy of organic growth (including volume and pricing), selective acquisitions and disciplined financial management.

The Group’s priorities are to increase its market share in diagnostic imaging, expand and optimise its laboratory network and explore new sales channels, including Longevity+, an innovative subscription model offering a wide range of preventive medicine services.

Multidimensional growth strategy with limited risk

The Group is expanding through a synergy of organic growth (including volume and pricing), selective acquisitions and disciplined financial management.

The Group’s priorities are to increase its market share in diagnostic imaging, expand and optimise its laboratory network and explore new sales channels, including Longevity+, an innovative subscription model offering a wide range of preventive medicine services.

Diagnostyka Group strives for profitable growth, guided by strategic priorities:

  1. 1

    Organic growth

    Supported by market growth, based on increasing volumes and prices
  2. 2

    Optimisation of laboratory and sample collection facility networks

    Economies of scale and improved cost efficiencies through rationalisation of sample collection facility networks and centralisation of laboratory and courier networks
  3. 3

    Strengthening central functions

    Development of central functions, back office and advanced IT and AI solutions
  4. 4

    Further expansion in the diagnostic imaging market

    Selective investment in M&A and organic growth
  5. 5

    Longevity

    Expansion into the area of preventive health¬ care, using the existing customer base and infrastructure

Current reports

All years strzałka w górę
  • All years
  • 2025
Notice of Extraordinary General Meeting of Diagnostyka S.A
Current reports : Current Report No. 12/2025
Date : 16.04.2025
Hour : 07:59

Date: 31 March 2025

Subject: Notice of Extraordinary General Meeting of Diagnostyka S.A

Legal basis: Art. 56.1.2 of the Public Offering Act – Current and periodic information

Text of the report:

Pursuant to Art. 399.1 of the Commercial Companies Code (the “Commercial Companies Code”), in response to the request submitted on 26 March 2025 pursuant to Art. 400.1 of the Commercial Companies Code by eligible shareholders (Grzegorz Głownia, Jacek Prusek and Jakub Swadźba) in Diagnostyka S.A. of Kraków (the “Company”) to convene an Extraordinary General Meeting of the Company (as announced by the Company in Current Report No. 11/2025 of 26 March 2025), the Management Board of the Company hereby gives notice of an Extraordinary General Meeting of the Company (the “EGM”) to be held at the Cogiteon Małopolska Science Centre, ul. Stefana Steca 1, Kraków, on 28 April 2025 at at 2:30 pm.

The following agenda has been proposed for the EGM:

  1. Opening of the Extraordinary General Meeting
  2. Appointment of the Chair of the Extraordinary General Meeting
  3. Confirmation that the Extraordinary General Meeting has been duly convened and has the capacity to pass binding resolutions
  4. Adoption of the agenda
  5. Voting on a resolution to appoint a member to the Supervisory Board of Diagnostyka S.A. of Kraków
  6. Voting on a resolution to appoint a member to the Supervisory Board of Diagnostyka S.A. of Kraków
  7. Voting on a resolution to appoint a member to the Supervisory Board of Diagnostyka S.A. of Kraków
  8. Voting on a resolution to determine the remuneration of Diagnostyka S.A. Supervisory Board members
  9. Voting on a resolution to cover the costs of convening and holding the Extraordinary General Meeting
  10. Closing of the General Meeting

Attached is the Company’s notice of the Extraordinary General Meeting, made pursuant to Article 402.2 of the Commercial Companies Code, along with the draft resolutions to be voted on by the Meeting.

 

Legal basis: Section 19.1.1 and 2 of the Minister of Finance’s Regulation on current and periodic information to be published by issuers of securities and conditions for recognition as equivalent of information whose disclosure is required under the laws of a non-member state, dated 29 March 2018.

For the Company:

Paweł Chytła – Vice President of the Management Board

Jaromir Pelczarski – Vice President of the Management Board

Update to the information on the publication dates of Diagnostyka S.A.’s periodic reports in 2025
Current reports : Current Report No. 13/2025
Date : 04.04.2025
Hour : 08:00

Date : 4 April 2025

Temat: Update to the information on the publication dates of Diagnostyka S.A.’s periodic reports in 2025

Text of the report:

In reference to current report no. 8/2025 dated March 11, 2025, the Management Board of Diagnostyka S.A. (the “Company”) hereby provides the dates for the publication of the Company’s periodic reports in 2025. In accordance with § 62 sections 1 and 3 of the Regulation, the Company informs that the consolidated quarterly and half-year reports will include, respectively, quarterly standalone financial information and a condensed standalone half-year financial statement. Therefore, the Company will not publish separate standalone quarterly reports or a separate standalone half-year report.

Accordingly, the Company updates the information on the dates of publication of its periodic reports in 2025 (removing information about standalone quarterly and half-year reports) and provides the new schedule of publication dates:

(1) 2024 separate and consolidated full-year reports – April 24, 2025

(2) 2025 interim reports:

– consolidated quarterly reports for the first quarter of 2025 – 27 May 2025

– consolidated half-year reports for the first half of 2025 – 18 September 2025

– consolidated quarterly reports for the third quarter of 2025 – 20 November 2025

Specific legal basis:

Section 80.4 of the Minister of Finance’s Regulation on current and periodic information to be published by issuers of securities and conditions for recognition as equivalent of information whose disclosure is required under the laws of a non-member state of 29 March 2018

For the Company:
Jakub Swadźba – President of the Management Board
Paweł Chytła – Vice President of the Management Board

Request to convene Extraordinary General Meeting of Diagnostyka
Current reports : Current Report No. 11/2025
Date : 03.04.2025
Hour : 07:05

Date: 26 March 2025

Subject: Request to convene Extraordinary General Meeting of Diagnostyka

Legal basis: Article 17(1) of MAR – Inside information

Text of the report:

The Management Board of Diagnostyka S.A. (the “Company”) announces that on 26 March 2025 it received a request to convene an Extraordinary General Meeting from the Company’s shareholders Grzegorz Głownia, Jacek Prusek and Jakub Swadźba, representing jointly one-twentieth or more of the Company’s share capital. The request includes a motion to vote on resolutions on the appointment of three members to the Supervisory Board (Patrycja Swadźba, Paweł Leżański and Piotr Solorz), as well as to pass a resolution regarding remuneration of the Supervisory Board members.

The request is attached as an appendix hereto.

The Management Board also announces that the General Meeting will be convened in accordance with applicable laws, and the notice and agenda of the General Meeting will be published in a separate report and posted on the Company’s website.

 

Specific legal basis: Article 17(1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC (OJ L 173) (“MAR”).

For the Company:

Jakub Swadźba – CEO, President of the Management Board

Paweł Chytła – Vice President of the Management Board

Resignation by Supervisory Board Members
Current reports : Current Report No. 10/2025
Date : 03.04.2025
Hour : 07:04

Date: 26 March 2025

Subject: Resignation by Supervisory Board Members

Legal basis: Art. 56.1.2 of the Public Offering Act – Current and periodic information

Text of the report:

The Management Board of Diagnostyka S.A. (the “Company”) announces that on 26 March 2025, it received resignation letters from Matthew Strassberg and Paweł Malicki, members of the Company’s Supervisory Board. Their resignations will take effect on the date of the next General Meeting or, at the latest, on 30 June 2025.

 

Specific legal basis: Section 5.4 of the Minister of Finance’s Regulation on current and periodic information to be published by issuers of securities and conditions for recognition as equivalent of information whose disclosure is required under the laws of a non-member state of 29 March 2018.

For the Company:

Jakub Swadźba – CEO, President of the Management Board

Paweł Chytła – Vice President of the Management Board

Notification prepared in accordance with Article 19 (3) of the MAR Regulations.
Current reports : Current Report No. 9/2025
Date : 13.03.2025
Hour : 08:48

Date: 12 March 2025

Subject: Notification prepared in accordance with Article 19 (3) of the MAR Regulations.

Legal basis: Information about transaction on the Company’s shares

Text of the report:

The Management Board of the Diagnostyka S.A (the ”Company”) hereby announces that on 12 March 2025, the Company received from Mr. Jaromir Pelczarski, Vice President of the Management Board of Diagnostyka S.A.,  a notification prepared pursuant to Article 19 of the MAR Regulations. The notification is attached to this current report.

For the Company:

Jakub Swadźba  – President of the Management Board

Paweł Chytła – Vice President of the Management Board

Periodic reports

All years strzałka w górę
  • All years
Reports
Update with future reports.

Good Practices of Companies Listed on the GPW (DPSN)

Reports
Update with future reports.

Financial results

Download data in XLS format
Data in PLN thous 2021 2022 2023 9M 2024
Operating income 1) 1,847,954 1,444,243 1,597,029 1,459,780
Revenue from contracts with customers 1) 1,842,776 1,435,584 1,587,979 1,444,866
of which related to COVID-19 2) 715,795 152,365 3,381 0
Operating expenses 1) (1,160,117) (1,201,302) (1,362,769) (1,200,208)
Operating profit 1) 687,837 242,941 234,260 259,572
Recurring EBITDA 2) 3) 807,892 373,122 383,025 383,370
Net profit (loss) 1) 562,434 171,660 129,988 176,007

1) Audited figures for 2023, 2022, 2021 and unaudited figures for the nine months ended 30 September 2024.

2) Unaudited data.

3) The Group defines EBITDA as net profit (loss) adjusted for income tax, share in results of associates or jointly controlled entities, impairment losses on investments in associates or jointly controlled entities for the period, finance costs, finance income and depreciation and amortisation. The Group defines Recurring EBITDA as EBITDA further adjusted for costs associated with the IPO, share-based payment programme and other non-recurring adjustments (e.g. costs of advisory fees related to transaction advisory services).

Shareholding structure

Update for future transa strzałka w górę
  • Update for future transa
  • Dividend policy
  • Stock quotes
Update for future transa Dividend policy Stock quotes

Update for future transa

Shareholder Number of shares (%) of shares (%) of votes
Grzegorz Głownia 1) 6,372,379 18.88 25.65
Jacek Prusek 2) 6,372,379 18.88 25.65
Jakub Swadźba 3,186,189 9.44 12.82
Others 17,825,553 52,81 35,88
Total 33,756,500 100 100

1) Directly and through ACER Capital Partners SCSp

2) Directly and through ACACIA Capital Partners SCSp

 

Dividend policy

In future years, the Management Board intends to recommend the payment of dividends to shareholders for the financial year. Subject to market conditions and the factors set out below, the Management Board intends to recommend to the General Meeting that a dividend of the Company’s 50% net profit attributable to Shareholders of the Parent Company, with the possibility of an increase in years of exceptionally strong financial performance, as assessed by the Management Board.

In making its recommendation, the Management Board will take into account:

  • restrictions of a business nature (in particular restrictions on dividend payments contained in the Group’s financing agreements) and restrictions of a legal nature affecting the amount of dividend payments that may be paid to shareholders,
  • the Group’s financial standing (in the context of extraordinary economic circumstances or significant capital needs),
  • the Group’s strategy and development plans.

The Management Board does not guarantee the amount of profit achieved by the Company in the future or the portion of it that can be allocated to the payment of dividends. The decision to pay dividends and the amount of dividend payments to be paid is in any case at the discretion of the shareholders in the General Meeting, the shareholders being in no way bound by the recommendation of the Management Board.

Stock quotes

Monitoruj wszystkie rynki na TradingView

Company Authorities

Our Management Board

  • Jakub Swadźba

    Jakub Swadźba

    President of the Management Board

  • Dariusz Zowczak

    Dariusz Zowczak

    Vice-President of the Management Board

  • Marta Rogalska-Kupiec

    Marta Rogalska-Kupiec

    Vice-President of the Management Board

  • Paweł Chytła

    Paweł Chytła

    Vice-President of the Management Board

  • Jaromir Pelczarski

    Jaromir Pelczarski

    Vice-President of the Management Board

Supervisory Board

  • Artur Olender

    Chairman of the Supervisory Board

  • Jacek Prusek

    Member of the Supervisory Board

  • Grzegorz Głownia

    Member of the Supervisory Board

  • Marcin Fryda

    Member of the Supervisory Board

  • Paweł Malicki

    Member of the Supervisory Board

  • Matthew Strassberg

    Member of the Supervisory Board

  • Aniela Hejnowska

    Member of the Supervisory Board

Historical background

The Group’s history is marked by the following milestones:

  1. 1998

    Establishment of Diagnostyka s.c. in Kraków and opening of the first laboratory

  2. 2000

    Establishment of Diagnostyka Gorzów Wielkopolski and takeover of Medica Zielona Góra

  3. 2001

    Establishment of Diagnostyka Warszawa and merger with Diagnostyka Kraków

  4. 2004

    Implementation of the management system and ISO 9001 certification

  5. 2006

    Opening of a branch in Wrocław and own molecular biology laboratory in Kraków

  6. 2008

    Dynamic development of the Group’s activities through the creation and acquisition of new entities, including: ODM Kielce, Diagnostyka Częstochowa, Loma Opole, Top-Lab Lublin

  7. 2010

    Obtaining ISO/IEC 17025 accreditation confirming the competence of testing laboratories

  8. 2011

    Acquisition of a separate organised part of the company and acquisition of the “Dr n. med. Teresa Fryda Laboratorium Medyczne”

  9. 2011

    Securing the financial investor MID Europa Partners and merger with a company owned by Marcin Fryda, who becomes a shareholder of the Company

  10. 2011

    Obtaining ISO 15189 accreditation confirming the competence of medical diagnostic laboratories

  11. 2012

    Acquisition of Medis and Alpha Medical — ensuring the presence of Diagnostyka in every voivodeship in Poland

  12. 2013

    Acquisition of Olympus Consilio (now Diagnostyka Consilio) based in Łódź, which initiated the Group’s entry into the market for histopathology diagnostic services

  13. 2014

    Opening of the new Diagnostyka headquarters in Kraków and the largest Central Network Laboratory in Poland (and one of the most advanced in the world)

  14. 2016

    Implementation of an information security system and obtaining ISO/IEC 27001 certification

  15. 2016

    Acquisition of the majority of shares in Oncogene Diagnostics sp. z o.o.

  16. 2017

    Launch of the Group’s e-commerce platform

  17. 2017

    Implementation of an environmental system and obtaining ISO 14001 certification

  18. 2018

    Acquisition of one of the largest and most advanced genetic laboratories — Genesis Medical Genetics Centres from Poznań

  19. 2018

    Acquisition of Vitalabo Laboratoria Medyczne sp. z o.o. with a well-established position on the laboratory market in northern Poland having, at the time of acquisition, three central laboratories and approximately 100 sample collection facilities

  20. 2018

    The establishment of Diagnostyka Consilio sp. z o.o. Poznań sp.k. and acquisition of new histopathology specialists, thereby increasing market share in the histopathology services market in Wielkopolskie Voivodship

  21. 2018

    Expanding the possibility of safe blood collection at the patient’s home, thanks to cooperation with the uPacjenta.pl platform

  22. 2019

    Acquisition of the Histamed histopathology laboratory in Gliwice (now Histamed DC sp. z o.o.)

  23. 2020

    Group’s involvement in the fight against the coronavirus pandemic — performing free SARS-CoV-2 testing for medics and teachers and performing 10% of all COVID-19 tests performed in Poland

  24. 2021

    Acquisition of one of Poland’s largest e-commerce sites dedicated to diagnostic tests — ZdroweGeny.pl

  25. 2021

    Group’s investment in a start-up for doctors — Badania.pl

  26. 2021

    Opening of a central laboratory in Warsaw equipped with the most advanced laboratory technology in Europe

  27. 2021

    Transformation into a joint stock company

  28. 2021

    Publication of the first ESG report

  29. 2022

    Involvement of the Group in providing in-kind and financial assistance to victims of the conflict in Ukraine and offering free examinations to refugees

  30. 2023

    Acquisition of the company NZOZ Diagno-Med. sp. z o.o. strengthening the Group’s position in the market of the Śląskie Voivodeship.

  31. 2023

    Commencement of the Group’s activities in the area of diagnostic imaging — acquisition of the company Zakład Rentgen i USG Wyrobek

  32. 2023

    25th anniversary of the Diagnostyka Group. Rebranding and refreshment of the company’s visual identity.

  33. 2024

    Acquisition of the company Telediagnostyka sp. z o.o. and the company Livmed sp. z o.o. continuing the Group’s expansion in the diagnostic imaging market

  34. 2025

    Initial Public Offering of shares in Diagnostyka S.A. and debut on the Warsaw Stock Exchange
Poprzedni
Następny

Investor calendar

  • Separate and consolidated full-year reports for 2024

  • Separate and consolidated quarterly reports for the first quarter of 2025

  • Separate and consolidated half-year reports for the first half of 2025

  • Separate and consolidated quarterly reports for the third quarter of 2025

Upcoming events

Contact

Downloads

Link to an IPO page

Go